⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 26, 2002Neurology

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson’s disease

Myung Sik Lee H. S. Kim E. K. Cho Ji Hyae Lim Juha O. Rinne

View at Publisher

Ask AI

Bookmark

Share

Abstract

The COMT genotype seems to be a minor factor in judging the beneficial effects of entacapone administration.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2002) studied this question.

synapsesocial.com/papers/69d917a116f0d2beeba3c041 https://doi.org/10.1212/wnl.58.4.564

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pharmacokinetics of LevodopaOriginal Research · 1984 · 356 citations
2Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literatureReview · 2001 · 1,455 citations
3Kinetics of Human Soluble and Membrane-Bound Catechol O-Methyltransferase: A Revised Mechanism and Description of the Thermolabile Variant of the EnzymeOriginal Research · 1995 · 1,167 citations
4Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in FinlandOriginal Research · 1997 · 151 citations
5The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.Original Research · 1988 · 3,481 citations

More related papers

Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients1994
Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients1987
3‐<i>O</i>‐Methyldopa and the response to levodopa in Parkinson's disease1987

More from Neurology

Recanalization After Acute Cervical Artery DissectionTue,
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSDTue,